Real-Life Efficacy, Immunogenicity and Safety of Biosimilar Infliximab

Zsuzsanna Vegh, Zsuzsanna Kurti, P. Lakatos

Research output: Contribution to journalArticle

3 Citations (Scopus)


Recently, the use of biosimilar infliximab (IFX) in the treatment of inflammatory bowel diseases has become widespread in some European and non-European countries. Data on the efficacy, safety and immunogenicity from real-life cohorts are accumulating. The first reports showed similar outcomes in the induction and maintenance of remission, mucosal healing, safety and immunogenicity profile to the originator IFX. In the present review, we aimed to summarize the existing knowledge on the efficacy, safety and immunogenicity profile of biosimilar IFX reported from real-life cohorts.

Original languageEnglish
Pages (from-to)101-106
Number of pages6
JournalDigestive Diseases
Issue number1-2
Publication statusPublished - Feb 1 2017



  • Adverse events
  • Biosimilar
  • Efficacy
  • Immunogenicity
  • Infliximab

ASJC Scopus subject areas

  • Gastroenterology

Cite this